Prostate Cancer

Disease State Hub

FDA Alerts

Prostate Cancer

FDA: New Options for Opioid Dependence, MS, Prostate Cancer

05/31/2016

Primary care practitioners should be aware of 3 new FDA approvals that may be useful when treating patients with opioid dependence, prostate cancer, and multiple sclerosis.

05/31/2016

Research Summaries

Research Summary

Image-Guided Adaptive Radiation Treatments Reduces Short-Term Side Effects in Patients With Prostate Cancer

10/06/2023

Jessica Ganga

A team of researchers compared the presence of short-term side effects using two image-guided radiation treatment—magnetic resonance imaging-guided daily adaptive prostate stereotactic body radiotherapy...

10/06/2023

Conference Coverage

Hypercholesterolemia and Diabetes Have Little Impact on Major Adverse Cardiovascular Events Risk in Patients With Prostate Cancer

05/16/2023

Jessica Bard

Hypercholesterolemia and diabetes have a minimal impact on major adverse cardiovascular events (MACE) risk in patients with prostate cancer (PCa) who are treated with androgen deprivation therapy (ADT),...

05/16/2023

Prostate Cancer

Presurgical NHAs May Improve Outcomes For Patients With High-Risk Prostate Cancer

11/21/2022

The researchers set out to determine whether neoadjuvant novel hormonal agent (NHA) therapy before radical prostatectomy can improve outcomes in men with high-risk prostate cancer.

11/21/2022

treatment options

Oncologist vs Urologist Treatment Decision-Making for Metastatic Castration–Sensitive Prostate Cancer in the United States

06/03/2022

Study findings presented at the 2022 ASCO Annual Meeting reveal oncologists’ and urologists’ reasons for underutilization of treatment intensification for patients with metastatic castration–sensitive...

06/03/2022

treatment

FDA Approves New Prostate Cancer Treatment

04/22/2022

The US Food and Drug Administration has approved a new treatment for metastatic castration-resistant prostate cancer.

04/22/2022

November 2024

Current Issue

November 2024